Welcome to our dedicated page for Reunion Neuroscience news (Ticker: REUN), a resource for investors and traders seeking the latest updates and insights on Reunion Neuroscience stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Reunion Neuroscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Reunion Neuroscience's position in the market.
Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) announced its participation in two key investor conferences in September 2022. The first is the H.C. Wainwright 24th Annual Global Investment Conference, where a virtual fireside chat will occur from September 12-14. A recording will be available for 90 days. The second event is the Jefferies Innovation in Mental Health Summit on September 22, also featuring a fireside chat. Reunion focuses on developing innovative psychedelic-inspired therapies for mental health, including its lead compound, RE-104, targeting postpartum and treatment-resistant depression.
Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) announced its 2022 Annual General Meeting (AGM) scheduled for September 29, 2022, at 10:00 AM ET. Shareholders of record as of August 23, 2022, can vote and ask questions online. The AGM will be accessible virtually, and registration is required for teleconference dial-in. Key documents, including the Notice of Meeting and Management Information Circular, are available on SEDAR and EDGAR. Reunion focuses on innovative psychedelic therapeutics for mental health, including its lead asset, RE-104, aimed at treating post-partum depression.